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Abstract
Introduction: Recent evidence suggests a link between constitutional telomere length (TL) and cancer risk. Previous studies
have suggested that longer telomeres were associated with an increased risk of melanoma and larger size and number of
nevi. The goal of this study was to examine whether TL modified the risk of melanoma in melanoma-prone families with and
without CDKN2A germline mutations.
Materials and Methods: We measured TL in blood DNA in 119 cutaneous malignant melanoma (CMM) cases and 208
unaffected individuals. We also genotyped 13 tagging SNPs in TERT.
Results: We found that longer telomeres were associated with an increased risk of CMM (adjusted OR=2.81, 95% CI=1.02–
7.72, P=0.04). The association of longer TL with CMM risk was seen in CDKN2A- cases but not in CDKN2A+ cases. Among
CMM cases, the presence of solar injury was associated with shorter telomeres (P=0.002). One SNP in TERT, rs2735940, was
significantly associated with TL (P=0.002) after Bonferroni correction.
Discussion: Our findings suggest that TL regulation could be variable by CDKN2A mutation status, sun exposure, and
pigmentation phenotype. Therefore, TL measurement alone may not be a good marker for predicting CMM risk.
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Introduction
Cutaneous malignant melanoma (CMM) is an etiologically
heterogeneous disease with genetic, host, environmental factors,
and their interactions contributing to its development. The main
environmental risk factor is ultraviolet radiation (UVR), which
may influence melanoma risk through multiple mechanisms, such
as directly causing DNA damage, influencing the expression of
apoptosis-related molecules and inducing immunosuppression. [1]
Host phenotypic factors such as having a large number of benign
and dysplastic nevi (DN), blond or red hair color, light eye color,
freckling, and poor tanning ability have also been associated with
increased melanoma risk. [2] Approximately 10% of CMM cases
occur in a familial setting. [3] To date, two high-risk melanoma
susceptibility genes, CDKN2A on chromosome 9p21 and CDK4 on
12q14, have been identified. Germline mutations of the CDKN2A
gene have been described in approximately 20% of familial
melanoma kindreds. [4–5] Mutations of CDK4 are rare, and only a
few families worldwide have been found to harbor mutations.
Although germline CDKN2A mutations are associated with a high
risk of CMM, the penetrance of this gene is incomplete and varies
by age and geographical location. [6] Additionally, phenotypic
manifestations such as age at diagnosis, presence/number of DN,
number of melanomas, and cosegregation of pancreatic cancer
vary significantly among mutation carriers even within a single
PLOS ONE | www.plosone.org 1 August 2013 | Volume 8 | Issue 8 | e71121family. These findings suggest that other factors modify the effect
of CDKN2A.
Telomeres are located at the ends of chromosomes, and consist
of tandem nucleotide repeats (TTAGGG)n, the telomerase
enzyme, the shelterin protein complex, and many other accessory
proteins. They maintain genomic stability and chromosomal
integrity by protecting chromosome ends from degradation, end-
to-end fusion, and atypical recombination. [7] Telomeres shorten
with each cell division, due to ineffective replication of the 39 end
of DNA. [8] The telomerase enzyme complex consists of the
reverse transcriptase, TERT, and additional proteins which are
essential to maintain telomere length (TL). Telomerase is
upregulated in the majority of cancers [9] and in the immortal-
ization of skin keratinocytes. [10] Previous studies have shown that
genetic variation in TERT was associated with melanoma risk.
[11] Recently, a germline mutation in the promoter of TERT was
identified in a melanoma-prone family that caused a 2–4 fold
increase of TERT transcription. [12] Multiple mutations in the
TERT promoter were also found in primary melanoma tissues
with high frequency (33%),[12–13] suggesting that the dysregu-
lation of TERT may play an important role in the genesis of
melanoma.
TL is influenced by multiple factors, including both genetic and
environmental. A twin study indicated 78% heritability for mean
TL in blood [14], and subsequent studies mapped several
candidate loci for TL using linkage and genome-wide association
analyses. [15–20] Telomeres are highly sensitive to damage by
oxidative stress, alkylation, and UVR, which can cause telomere
shortening without DNA replication by inducing telomeric
double-strand breaks at high frequency. [21] Epidemiologic
studies examining the association between constitutional TL and
cancer risk have generated inconsistent results. Although short-
ened TL has been associated with increased risk of a number of
cancers such as bladder, gastric, and head and neck [22],
associations between longer TL and increased risk were reported
for other cancer types including Non-Hodgkin Lymphoma [23],
Hepatitis B Virus-Related Hepatocellular Carcinoma [24], and
melanoma. [25–26] Similarly, a previous study also found that
longer telomeres were associated with larger size and number of
melanocyte nevi. [27] These findings suggest that the association
of TL with cancer risk is complex and cancer-type specific, which
can be tumor suppressing or promoting depending on the host or
cell type’s susceptibility to genetic and environmental exposures.
The goal of our study was to examine whether TL modified the
risk of melanoma in melanoma-prone families in which the disease
etiology involved major genetic factors, at-risk host pigmentation
phenotypes, and environmental exposures.
Materials and Methods
Study Population
The details of this family study have been previously described.
[28–29] In brief, US families with at least two living first degree
relatives with a history of invasive melanoma were ascertained
through health care professionals or self-referrals. All family
members willing to participate in the study underwent a full-body
skin examination for phenotypes (type and total number of nevi,
extent of freckling, skin complexion, evidence for solar injury, and
hair and eye color) and completed risk factor questionnaires for
sun-related exposures such as tanning ability. All diagnoses of
melanoma were confirmed by histologic review of pathologic
material, pathology reports, or death certificates for deceased
CMM cases. The study was approved by the National Cancer
Institute Clinical Center Institutional Review Board and conduct-
ed according to the Declaration of Helsinki. Informed consent was
obtained from all participants.
The current study was based on 53 families (23 families
segregating CDKN2A mutations [CDKN2A+] and 30 families
without known mutations [CDKN2A-]). All study participants were
Caucasian. Two controls were selected for each case. The study
population for genotyping was comprised of 183 CMM cases and
379 unaffected individuals. TL data was available from a subset of
individuals (119 CMM cases and 208 unaffected individuals). The
unaffected individuals included 144 unaffected family members
and 64 genetically unrelated spouses. Demographic and CMM
risk factors did not differ significantly among subjects who were
included and not included in the TL analysis (data not shown).
Telomere Length Measurement
DNA was extracted from whole blood (N=267) whenever
available and from EBV-transformed lymphocytes (N=60) when
whole blood DNA was not available. Quantitative PCR was used
to measure telomere length. The average, relative TL was
estimated from the ratio of the telomere (T) repeat copy number
to a single gene copy number (36B4 gene; S), expressed as the T/S
ratio for each sample using standard curves. All samples for both
the telomeres and single-copy gene reactions were performed in
triplicate. Three blind replicate samples were interspersed with the
samples to assess inter-plate variability. The coefficients of
variation (CVs) within triplicates of the telomere assay, single-
gene assay, and T/S ratio were 0.87%, 0.65%, and 6.67%
respectively. The inter-assay CVs were 0.98%, 1.62%, and 7.92%
respectively.
SNP Genotyping
13 tag SNPs in TERT were genotyped at the NCI Core
Genotyping Facility (Advanced Technology Center, Gaithersburg,
MD; http://snp500cancer.nci.nih.gov) using a custom-designed
iSelect Infinium assay (Illumina, www.illumina.com), which
included a total of 27,904 tag SNPs that were selected for a
variety of cancers. Tag SNPs were selected using a minimum
minor allele frequency (MAF) criterion of MAF$5% based upon
HapMap data for Caucasian (CEU) and Yoruban (YRI) samples
using Tagzilla, software that implements a tagging algorithm based
on pairwise linkage disequilibrium. [30] SNPs within the region
spanning 20 kb 59 of the start of transcription (exon 1) to 10 kb 39
of the end of the last exon were grouped using a binning threshold
of r
2.0.8 to define a gene/region. When there were multiple
transcripts available for genes, only the primary transcript was
assessed. SNPs with low completion (,90%) and low concordance
(,95%) were excluded. Among 586 genotyped samples, 20 were
excluded due to either low completion (,90%, n=12) or
Mendelian inconsistencies (n=8). Four individuals were further
removed from all analyses due to missing CMM status.
Statistical Analysis
The Wilcoxon-Mann-Whitney test was used to assess whether
TL differed significantly between spouse controls and unaffected
family members. TL was not significantly different in the two
control groups (P=0.63), therefore we combined all controls in the
analyses. The Wilcoxon-Mann-Whitney test was used to assess
whether TL differed significantly between DNA from whole blood
and DNA from EBV-transformed lymphocytes. TL did not differ
significantly by DNA source in unaffected individuals (P=0.47) or
in CMM cases (P=0.09), however we still adjusted for DNA
source in all regression models. We also performed a sensitivity
analysis by restricting the evaluation to individuals whose DNA
was extracted from whole blood. Spearman correlation was used
Telomere Length and the Risk of CMM
PLOS ONE | www.plosone.org 2 August 2013 | Volume 8 | Issue 8 | e71121Table 1. Distribution of age, gender, CDKN2A, pigmentation phenotype, and sun exposure variables in 53 melanoma-prone
families by CMM status.
Unaffected Individuals (n=208) CMM Cases (n=119)
N% N % P
1
Age at Blood Draw
#30 41 19.7 16 13.4
30–40 49 23.6 25 21
40–50 46 22.1 34 28.6
50–60 40 19.2 22 18.5
60+ 32 15.4 22 18.5 0.45
Gender
Female 121 58.2 59 49.6
Male 87 41.8 60 50.4 0.13
CDKN2A
Non-Carrier 178 85.6 59 49.6
Carrier 30 14.4 60 50.4 ,.0001
Moles
0–24 58 29.4 7 6.4
25–49 37 18.8 14 12.8
50–99 53 26.9 17 15.6
100+ 49 24.9 71 65.1 ,.0001
Solar injury
None/mild 133 67.2 54 50.5
Moderate 42 21.2 31 29
Severe 23 11.6 22 20.6 0.01
MC1R
Wild type 35 24.8 7 7.2
1 nonsynonymous variant 63 44.7 46 47.4
2 nonsynonymous variants 43 30.5 44 45.4 0.001
Tanning ability
Tan/Little burn 94 51.9 46 46.9
Burn/Little tan 87 48.1 52 53.1 0.43
Skin type
Dark/medium 64 32.7 18 16.8
Pale/fair 132 67.3 89 83.2 0.003
Eye color
Black/brown 54 27.8 25 22.9
Hazel 44 22.7 28 25.7
Green/gray 16 8.2 11 10.1
Blue 80 41.2 45 41.3 0.76
Hair color
Black/brown 93 47.4 50 45.9
Blond brown/light brown 56 28.6 32 29.4
Blond 28 14.3 11 10.1
Red 19 9.7 16 14.7 0.47
Freckles
None/few 67 40.6 18 20
Moderate 40 24.2 29 32.2
Many 58 35.2 43 47.8 0.004
1P-values were obtained by comparing CMM cases to unaffected individuals using the chi-square test.
doi:10.1371/journal.pone.0071121.t001
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both as continuous variables.
We defined tertiles of TL distribution using cut-points based on
the distribution among all unaffected individuals (Short: ,0.53;
Medium: 0.53–0.72; Long: .0.72) and evaluated the associations
between TL and CMM risk factors using a generalized estimating
equation approach that accounts for familial correlation in the
variance computation, age at blood draw, gender, and DNA
source. Conditional logistic regression was used to obtain the odds
ratios (OR) and 95% confidence intervals (CIs) for the association
between CMM risk and TL, with the shortest telomere tertile used
as the reference group. We included age at blood draw, gender,
and DNA source in the basic model, and further adjusted for
germline CDKN2A mutation status, number of nevi, solar injury,
and MC1R (as a surrogate for pigmentation characteristics) [28] in
the final model. Conditioning on families was used to account for
family ascertainment and differences in disease prevalence among
families. While this approach ignores residual familial correlations
among family members, it gives estimates that are attenuated
toward the null and is thus conservative [31].
We used conditional logistic regression models to estimate the
trend p-value for the association between CMM and each TERT
SNP, using codominant coding for genotypes (0,1,2) with the
homozygote of the common allele as the reference group, and
adjusted for age at exam/diagnosis and gender. The associations
between TL and genotypes were assessed using a generalized
estimating equations (GEE) approach to account for correlation
among family members [32], adjusted for age at blood draw,
gender, and CMM. ORs and 95% CIs were computed using
cumulative logistic regression for ordinal outcomes (PROC
GENMOD, SAS 9.1). The working correlation matrix was the
independent correlation matrix. We used a Bonferroni correction
to account for the number of SNPs and outcomes (CMM and TL)
tested, and thus used P,0.05/26 (0.002) to define statistical
significance. All statistical tests were two-sided and data was
analyzed using SAS version 9.1 (SAS Institute, Cary, NC).
Results
In total, there were 119 CMM cases and 208 unaffected
individuals included in the TL analysis. As expected, CDKN2A
mutations, pale or fair skin type, increased number of nevi,
increased number of freckles, solar injury, and MC1R variants
were significantly associated with CMM risk in these families
(Table 1).
As expected, TL was negatively correlated with age at blood
draw among both unaffected individuals (r=20.14) and CMM
cases (r=20.12) (Figure 1). Among unaffected individuals, TL did
not differ significantly by any CMM risk factor examined (Table 2).
Among CMM cases, shorter telomeres were significantly associ-
ated with the presence of moderate or severe solar injury
(P=0.017) after adjusting for age at blood draw, gender, and
DNA source (whole blood or EBV-transformed lymphocytes).
Longer telomeres appeared to be associated with increased
number of moles in both unaffected and CMM individuals,
however, the association was not significant in either phenotype
group after the covariate adjustment.
Although solar injury was more common among CMM cases
than unaffected individuals, CMM cases had longer telomeres
(36.1% in the longest tertile) compared to unaffected individuals
(33.2%) (Table 3). After adjustment for age at blood draw, gender,
DNA source, CDKN2A carrier status, number of nevi, solar injury,
and MC1R, individuals in the longest TL category had close to a 3-
fold increase in CMM risk compared to individuals in the shortest
TL category (OR=2.81, 95% CI=1.02–7.72, P=0.04) (Table 3).
When CDKN2A+ and CDKN2A- cases were separately compared to
unaffected individuals, we found that the association of longer TL
with CMM risk was seen in CDKN2A- cases (OR=3.34, 95%
CI=1.12–10.00, P=0.03; comparing longest to shortest TL) but
not in CDKN2A+ cases (OR=1.00, 95% CI=0.42–2.38, P=0.99)
(Table 4).
The association between CMM and TL did not change
significantly when we restricted the analysis to individuals whose
DNA was drawn from whole blood (age and gender adjusted
OR=1.83, 95% CI=0.85–3.90, P=0.12). Similarly, results did
not vary significantly by age at blood draw (,50 vs. $50 years),
time of blood draw in relation to CMM diagnosis (before vs. after
CMM diagnosis), age at CMM diagnosis (,40 vs. $40 years), or
number of melanomas (single vs. multiple) (data not shown).
We examined whether genetic variants in TERT were
associated with CMM risk and TL in blood. This analysis
included 562 individuals (183 CMM cases and 379 unaffected
individuals). Among the 13 tag SNPs genotyped in this analysis,
one SNP, rs2735940, was significantly associated with TL
(P=0.002) after Bonferroni correction. Another SNP,
Figure 1. Correlations between relative telomere length and
age at blood draw in unaffected individuals and CMM cases. P
values were obtained from the Spearman correlation test.
doi:10.1371/journal.pone.0071121.g001
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(P=0.003).
Discussion
In this exploratory analysis, we evaluated TL in blood in
relation to CMM, CDKN2A germline mutation status, and CMM
risk factors in 53 melanoma-prone families with and without
CDKN2A mutations. Consistent with a previous report that found
that longer telomeres were associated with the development of
sporadic CMM [26], we found that longer telomeres were also
associated with increased CMM risk in melanoma families,
although the association was only seen in cases without CDKN2A
mutations.
Although extremely short telomeres cause genomic instability
and therefore increase cancer risk, senescence induced by telomere
Table 2. Distribution of age, gender, CDKN2A, pigmentation phenotype, and sun exposure variables in 53 melanoma-prone
families by telomere length, stratified by CMM status.
Unaffected Individuals CMM Cases
Short (n=70) Medium (n=69) Long (n=69) Short (n=34) Medium (n=42) Long (n=43)
N% N% N % P
1 N% N % N% P
1
Age at blood draw
#50 42 30.9 50 36.8 44 32.4 16 21.3 26 34.7 33 44
50+ 28 38.9 19 26.4 25 34.7 0.009 18 40.9 16 36.4 10 22.7 0.03
Gender
Female 38 31.4 45 37.2 38 31.4 14 23.7 21 35.6 24 40.7
Male 32 36.8 24 27.6 31 35.6 0.77 20 33.3 21 35 19 31.7 0.2
CDKN2A
Non-Carrier 60 33.7 58 32.6 60 33.7 16 27.1 19 32.2 24 40.7
Carrier 10 33.3 11 36.7 9 30 0.37 18 30 23 38.3 19 31.7 0.09
Moles
0–49 34 35.8 34 35.8 27 28.4 6 28.6 8 38.1 7 33.3
50+ 31 30.4 33 32.4 38 37.3 0.83 22 25 31 35.2 35 39.8 0.61
Solar injury
None/mild 43 32.3 47 35.3 43 32.3 6 11.1 22 40.7 26 48.1
Moderate/Severe 22 33.8 20 30.8 23 35.4 0.19 22 41.5 16 30.2 15 28.3 0.017
MC1R
Wild type/1 variant 30 30.6 38 38.8 30 30.6 11 20.8 21 39.6 21 39.6
2 variants 16 37.2 8 18.6 19 44.2 0.61 14 31.8 15 34.1 15 34.1 0.51
Tanning ability
Tan/little burn 30 31.9 37 39.4 27 28.7 10 21.7 15 32.6 21 45.7
Burn/little tan 28 32.2 28 32.2 31 35.6 0.73 17 32.7 19 36.5 16 30.8 0.08
Skin type
Dark/medium 23 35.9 26 40.6 15 23.4 5 27.8 6 33.3 7 38.9
Pale/fair 40 30.3 41 31.1 51 38.6 0.15 23 25.8 32 36 34 38.2 0.97
Eye color
Black/brown 15 27.8 24 44.4 15 27.8 9 36 4 16 12 48
Hazel/green/ 49 35 42 30 49 35 0.89 19 22.6 35 41.7 30 35.7 0.65
gray/blue
Hair color
Black/brown 27 29 35 37.6 31 33.3 11 22 14 28 25 50
Blond brown/light 28 33.3 29 34.5 27 32.1 0.58 11 25.6 18 41.9 14 32.6 0.26
brown/blond
Red 9 47.4 3 15.8 7 36.8 0.5 6 37.5 7 43.8 3 18.8 0.09
Freckles
None/few 21 31.3 29 43.3 17 25.4 3 16.7 5 27.8 10 55.6
Moderate/many 33 33.7 27 27.6 38 38.8 0.06 18 25 28 38.9 26 36.1 0.3
1P-values were obtained by comparing individuals in the telomere tertiles using a generalized estimating equation accounting for familial correlation in the variance
and adjusting for age at blood draw, gender, and DNA source.
Short: ,0.53; Medium: 0.53–0.72; Long: .0.72.
doi:10.1371/journal.pone.0071121.t002
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provide a barrier for cancer growth [33]. On the other hand,
longer telomeres, which may result from upregulated telomerase
when cells reach a critically short TL but do not undergo
senescence or apoptosis, may be associated with increased
proliferative potential and cancer susceptibility. Constitutive
telomerase expression in TERT-deficient transgenic mouse models
resulted in increased incidence of epidermal tumors and skin
wound healing [34]. Therefore, longer telomeres, in combination
with decreased cell senescence, may greatly increase the prolifer-
ation potential of melanocytes, which leads to an increased
propensity for nevi and melanoma. Consistent with a previous
study which found that longer telomeres were associated with
larger size and number of nevi [27], we found that longer
telomeres were associated with an increased number of moles.
Interestingly, the association between longer TL and CMM risk
was seen in CDKN2A- cases but not in CDKN2A+ cases. One
possible reason is that melanomas in individuals with CDKN2A
mutations may develop from telomere-independent mechanisms.
Alternatively, the uncontrolled cell proliferation coupled with
impaired DNA repair caused by CDKN2A mutations may lead to
genomic instability and telomere shortening. CDKN2A-deficient
mice exhibited increased levels of intracellular reactive oxygen
species (ROS) in response to UVR [35] and demonstrated reduced
ability to process UVR-induced DNA damage [36]. In prolifer-
ating cells, telomere DNA can be lost due to the inability of the
DNA replication machinery to duplicate the linear DNA ends.
Consistent with this hypothesis, a recent study demonstrated that
telomere length shortening was significantly associated with
hypermethylation of CDKN2A promoters in breast cancer [37].
Due to a high content of guanines, telomeres are especially
sensitive to damage by oxidative stress [38]. Although the exact
mechanism is unknown, telomere shortening is likely caused by
oxidative DNA damage and deficiency in DNA repair in telomeric
regions [39]. Our observation that moderate or severe solar injury
was associated with shorter TL is in line with these findings. It is
not clear why the association only occurred among CMM cases
but not in unaffected individuals. One possibility is that solar
injury reflected the interaction of sun exposure and sun sensitivity,
and CMM cases are more likely to have sensitive skin types and be
deficient in DNA repair capacities.
Some, but not all of our findings are consistent with those of
Bodelon et al. based on a Mediterranean population [40]. In that
study TL was also significantly associated with age but not with
other CMM risk factors among unaffected individuals [40], but in
contrast to our results, TL was not associated with CMM risk. The
inconsistency is likely due to the differences in the populations, sun
exposure, pigmentation characteristics, family history of melano-
ma, and melanoma phenotypes (usually diagnosed at early-stage in
US because of more frequent screening) between the Mediterra-
nean and American populations.
In our study, one SNP in TERT (rs2735940) was significantly
associated with TL (P=0.002). Another SNP (rs4635969) in
TERT-CLPTM1L, a region that was previously associated with
multiple cancers including melanoma [41], showed a suggestive
association with TL (P=0.005). A common polymorphism
(rs2853669) in TERT, which was in complete allelic linkage with
the recently identified germline mutation in the promoter of
TERT, was unfortunately not genotyped in our study and not in
LD with any of our genotypted SNPs.
Our study was exploratory due to the limited number of
melanoma cases analyzed. In addition, in a small subset of
individuals DNA was extracted from EBV-transformed lympho-
cytes, which could potentially cause bias in TL measurement.
Table 3. Association of telomere length with melanoma in 53 melanoma-prone families
1.
Telomere Unaffected (n=208) CMM (n=119) Model 1
3 Model 2
4 Model 3
5
Tertile
2 N % N % OR 95% CI P OR 95% CI P OR 95% CI P
1st (short) 70 33.7 34 28.6 Ref Ref Ref
2nd (medium) 69 33.2 42 35.3 1.39 0.74–2.62 0.31 2.42 1.02–5.76 0.05 2.03 0.76–5.44 0.16
3rd (long) 69 33.2 43 36.1 1.38 0.73–2.63 0.33 2.89 1.20–6.94 0.02 2.81 1.02–7.72 0.04
1ORs and P-values were obtained from conditional logistic regression with melanoma as the outcome variable.
2Telomere tertile: Short: ,0.53; Medium: 0.53–0.72; Long: .0.72.
3Model 1: age at blood draw, gender, and DNA source adjustment.
4Model 2: age at blood draw, gender, DNA source, CDKN2A, and solar injury adjustment.
5Model 2: age at blood draw, gender, DNA source, CDKN2A, moles, solar injury, and MC1R adjustment.
doi:10.1371/journal.pone.0071121.t003
Table 4. Association of telomere length with melanoma in 53 melanoma-prone families, stratified by CDKN2A status among
cases
1.
Telomere Unaffected (n=208) CDKN2A+ CMM Cases (n=60) CDKN2A- CMM Cases (n=59)
Tertile
2 N % N % OR 95% CI P N % OR 95% CI P
1st (short) 70 33.7 18 30 Ref 16 27.1 Ref
2nd (medium) 69 33.2 23 38.3 1.4 0.58–3.36 0.46 19 32.2 2.45 0.81–7.44 0.11
3rd (long) 69 33.2 19 31.7 1 0.42–2.38 0.99 24 40.7 3.34 1.12–10.00 0.03
1ORs and P-values were obtained from conditional logistic regression with melanoma as the outcome variable. Age at blood draw, gender, DNA source, and solar injury
adjustment.
2Telomere tertile: Short: ,0.53; Medium: 0.53–0.72; Long: .0.72.
doi:10.1371/journal.pone.0071121.t004
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regression models. We also restricted the analysis to individuals
with DNA extracted from whole blood and the results showed
similar patterns. Another limitation was that our families were
ascertained primarily through self- or physician-referral, and thus
findings may not be generalizable to other familial melanoma
sample sets or to sporadic melanoma patients. The strengths of our
study include a rich collection of genetic, exposure, clinical, and
pigmentation data in melanoma-prone families with and without
known CDKN2A mutations. We confirmed results from previous
studies which found that longer telomeres were associated with
CMM risk. Furthermore, our findings suggest that TL in CMM
cases might be influenced by multiple mechanisms with opposing
directions. Genetic background associated with proliferation
potential and at-risk pigmentation phenotypes may predispose
CMM cases to longer TL, whereas CDKN2A mutations and sun
exposure may cause telomere shortening in these individuals.
Therefore, using TL alone as a potential biomarker to predict
CMM risk may oversimplify the complex role and regulation of
telomeres.
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